PTSD News

Approximately 60% of men and 50% of women will experience at least one trauma throughout their life and 10% of women and 4% of men will develop PTSD, according to the National Center for PTSD.

Analysis of a large cross-national community sample indicated previous traumatic experiences were generally associated with PTSD, though generalized risk was limited to previous exposure to violence and sexual assault.

Lower IQ was associated with past-year fear and distress disorders and was not associated with PTSD, anxiety or eating disorders, according to recent findings.

PTSD was common among women receiving mindfulness therapy for depression at an urban federally qualified health center, suggesting an association between trauma and residing in a disadvantaged neighborhood.

Tonix Pharmaceuticals recently announced the FDA granted Breakthrough Therapy Designation to TNX-102 SL, a low-dose sublingual formulation of cyclobenzaprine, for PTSD.

Fear circuitry and dysphoric PTSD symptoms became more strongly connected as time passed after traumatic injury, according to recent findings.

A subgroup analysis of phase 2 findings reaffirmed efficacy of TNX-102 SL, a low-dose sublingual formulation of cyclobenzaprine from Tonix Pharmaceuticals, for military-related PTSD, including traumas from combat.

Women who have experienced a miscarriage or ectopic pregnancy are at a greater risk for PTSD and should be screened regularly for the condition, according to study results published in BMJ Open.

Disruptions in the circuitry of cognitive emotional pathways in the brain may explain depression symptoms among service members who experienced mild traumatic brain injury, according to data presented at the Radiological Society of North America annual meeting.

Recent findings indicated sex-specific differences in insula volume among youth with PTSD, suggesting that trauma may present differently between boys and girls.